<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The relationship between cognitive function, <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and premature <z:hpo ids='HP_0011420'>death</z:hpo> is not well established in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the effects of cognitive function in 11,140 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who participated in the Action in <z:mp ids='MP_0002055'>Diabetes</z:mp> and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">Vascular Disease</z:e>: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('<z:mpath ids='MPATH_458'>normal</z:mpath>', n = 8,689), 24-27 ('mild dysfunction', n = 2,231) and &lt;24 ('severe dysfunction', n = 212) </plain></SENT>
<SENT sid="4" pm="."><plain>Risks of major cardiovascular events, <z:hpo ids='HP_0011420'>death</z:hpo> and <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> and interactions with treatment were assessed using Cox proportional hazards analysis </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Relative to <z:mpath ids='MPATH_458'>normal</z:mpath> function, both mild and severe <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunction</z:e> significantly increased the multiple-adjusted risks of major cardiovascular events (HR 1.27, 95% CI 1.11-1.46 and 1.42, 95% CI 1.01-1.99; both p &lt; 0.05), cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> (1.41, 95% CI 1.16-1.71 and 1.56, 95% CI 0.99-2.46; both p &lt;or= 0.05) and <z:hpo ids='HP_0000001'>all</z:hpo>-cause <z:hpo ids='HP_0011420'>death</z:hpo> (1.33, 95% CI 1.16-1.54 and 1.50, 95% CI 1.06-2.12; both p &lt; 0.03) </plain></SENT>
<SENT sid="6" pm="."><plain>Severe, but not mild, <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunction</z:e> increased the risk of severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> (HR 2.10, 95% CI 1.14-3.87; p = 0.018) </plain></SENT>
<SENT sid="7" pm="."><plain>There was no evidence of <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of treatment effects on cardiovascular outcomes in subgroups defined by cognitive function at baseline </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">Cognitive dysfunction</z:e> is an independent predictor of clinical outcomes in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, but does not modify the effects of BP lowering or <z:chebi fb="105" ids="17234">glucose</z:chebi> control on the risks of major cardiovascular events </plain></SENT>
<SENT sid="9" pm="."><plain>TRIAL REGISTRATION: ClinicalTrials.gov NCT00145925 </plain></SENT>
</text></document>